

October 28, 2020

Case # 611406

Via Electronic Mail

Mark W. Shinabery
Owner and Pharmacist-In-Charge
Custom Compounding Center
11700 Kanis Rd, Suite 1
Little Rock, Arkansas 72211
e-mail: Mark@customccrx.com

Dear Mr. Shinabery:

In a separate communication, we will be enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Custom Compounding Center located at 11700 Kanis Rd, Suite 1, Little Rock, Arkansas 72211, from May 29, 2019, to June 4, 2019, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing a letter sent to the Arkansas State Board of Pharmacy.

When the Agency considers an inspection to be "closed" under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

Page 2 – Mark W. Shinabery, Owner and Pharmacist-In-Charge **Custom Compounding Center** October 28, 2020

If there is any question about the released information, please contact Thao Ta, Compliance Officer, at 214-253-5217, or via e-mail at thao.ta@fda.hhs.gov.

Sincerely,



CDR John W. Diehl, M.S. Director, Compliance Branch Office of Pharmaceutical Quality Operations, Division II

Enclosure: EIR, SRL

CC:

VIA E-MAIL

John C. Kirtley, PharmD. (cover letter only) **Executive Director** Arkanasa State Board of Pharmacy 322 South Main Street, Suite 600 Little Rock, Arkansas 72201

e-mail: john.kirtley@arkansas.gov